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Abstract
Background The cytochrome P450s (CYPs) are a superfamily of
oxidative enzymes of which the CYP3A subfamily is responsible
for the metabolism of approximately 50% of all drugs. This
includes exogenous and endogenous steroids. Over 20
polymorphisms of CYP3A4 have been described with three
metabolic phenotypes: ultra-rapid, extensive and poor
metabolizers. The CYP3A4*1B has an allelic frequency of 2-9%
in Caucasians and is associated with increased enzymatic
activity. Clinical Case This is a 49-year-old Caucasian female
with a known history of Addison’s disease for 2 years,
Hashimoto’s thyroiditis, Osteoporosis, Celiac disease, Vitamin D
deficiency and Pernicious Anemia, who presented to the ER after
a syncopal episode following 3 days of nausea and vomiting. On
arrival, she was hypothermic, hypotensive and tachycardic with
a BP of 57/40 mmHg, pulse of 112 BPM. On exam she looked
cachectic with tanned skin, dark palmar creases and pigmented
oral mucosa. Initial labs showed normal CBC, low sodium (125, n
135 - 148 MEQ/L), hyperkalemia (5.8, n 3.5 - 5.3 MEQ/L), normal
blood glucose and renal function. Further testing showed low
AM cortisol <1.0 ug/dL (n 6.7-22.6 ug/dL), high ACTH (1010, n
6-50pg), TSH 7 (n 0.35 - 4.94 UIU/ML), Free T4 0.70 (n 0.70 1.48 NG/DL), TPO antibodies 759.06 (n<5.61 IU/ML), low
aldosterone level <1.0 (n 3 - 16 ng/dL), and high renin activity
19.53 (n 0.25 - 5.82 ng/mL/h). After IV fluids resuscitation and
IV steroids, she became hemodynamically stable and was
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transitioned to oral hydrocortisone 20 mg AM, 10 mg PM, and
fludrocortisone 0.1 mg daily. Five days later, she returned to the
hospital with adrenal crisis. Despite adherence to her
medications, she had several crises per month. Home regimen
was adjusted to 100 mg hydrocortisone PO every 6 hours
without resolution. During one of her hospitalizations, plasma
cortisol was undetectable one hour after 100 mg hydrocortisone
PO dose. EGD showed normal mucosa, thus malabsorption from
celiac disease unlikely. Her frequent adrenal crises and
undetectable levels of serum cortisol despite compliance,
prompted evaluation of Cytochrome P450 genotype which
revealed CYP3A4 Genotype B, allele 22, not detected. Patient was
diagnosed as a CYP3A4 ultra-rapid metabolizer. She is currently
being treated with Hydrocortisone 100mg IM every 4 hours and
fludrocortisone 0.2mg PO every 4 hours. Since these
adjustments, her adrenal crises are less frequent. Conclusion
Variability in the expression of CYP3A4 can cause unpredictable
interindividual drug responses. Exogenous steroids are not
exempt. In this patient with Addison’s disease,
pharmacogenomic testing helped us individualize her
maintenance dose to one that is intramuscular, and a higher
dose and frequency, than what would be suggested in the
current literature.
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